Entasis Therapeutics Holdings Inc. (ETTX) NASDAQ

$1.80 -0.03 (-1.64%)

Market Cap: $87.57M

As of 05/20/22 04:00 PM EDT. Market closed.

(ETTX)

Entasis Therapeutics Holdings Inc. (ETTX) NASDAQ

$1.80 -0.03 (-1.64%)

Market Cap: $87.57M

As of 05/20/22 04:00 PM EDT. Market closed.

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), ... read more

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
URL
entasistx.com
Address
.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
47
URL
entasistx.com
Address
.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
KEY STATS
Open
$0
Previous Close
$1.83
Days Range
$1.78 - $1.83
52 week range
$1.40 - $3.88
Volume
36,782
Avg. Volume (30 days)
46,472
Market Cap
$87.57M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
47,851,779
Open
$0
Previous Close
$1.83
Days Range
$1.78 - $1.83
52 week range
$1.40 - $3.88
Volume
36,782
Avg. Volume (30 days)
46,472
Market Cap
$87.57M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
47,851,779

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR ENTASIS THERAPEUTICS HOLDINGS INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Ronsheim Matthew Chief, Pharma Sciences & MFG. Nov 02, 2021 Option Exercise $2.94 3,669 10,787 42,572 Nov 03, 2021, 04:05 PM
Keiley Elizabeth M General Counsel Nov 02, 2021 Option Exercise $2.94 3,669 10,787 42,572 Nov 03, 2021, 04:04 PM
Altarac David Chief Medical Officer Nov 02, 2021 Option Exercise $2.94 3,669 10,787 42,572 Nov 03, 2021, 04:04 PM
Mueller John Patrick Chief Development Officer Nov 02, 2021 Option Exercise $2.94 3,907 11,487 42,092 Nov 03, 2021, 04:03 PM
Perros Manoussos President and CEO Nov 02, 2021 Option Exercise $2.94 11,704 34,410 135,822 Nov 03, 2021, 04:03 PM
Gutch Michael CFO and Chief Business Officer Nov 02, 2021 Option Exercise $2.94 3,669 10,787 42,572 Nov 03, 2021, 04:02 PM
Tommasi Ruben Chief Scientific Officer Nov 02, 2021 Option Exercise $2.94 3,669 10,787 64,596 Nov 03, 2021, 04:02 PM
Perros Manoussos See Remarks Oct 19, 2021 Sale $3.19 11,974 38,197 147,526 Oct 20, 2021, 04:14 PM
Mueller John Patrick Chief Development Officer Oct 19, 2021 Sale $3.19 4,001 12,763 45,999 Oct 20, 2021, 04:10 PM
Gutch Michael See Remarks Oct 19, 2021 Sale $3.19 3,759 11,991 46,241 Oct 20, 2021, 04:09 PM
Tommasi Ruben Chief Scientific Officer Oct 19, 2021 Sale $3.19 3,759 11,991 68,265 Oct 20, 2021, 04:08 PM
Keiley Elizabeth M General Counsel Oct 19, 2021 Sale $3.19 3,759 11,991 46,241 Oct 20, 2021, 04:08 PM
Altarac David Chief Medical Officer Oct 19, 2021 Sale $3.19 3,759 11,991 46,241 Oct 20, 2021, 04:06 PM
Ronsheim Matthew See Remarks Oct 19, 2021 Sale $3.19 3,759 11,991 46,241 Oct 20, 2021, 04:05 PM
Innoviva, Inc. 10% Owner Sep 01, 2020 Buy $2.67 4,672,897 12,499,999 18,672,897 Sep 01, 2020, 05:31 PM
Innoviva, Inc. 10% Owner Jun 11, 2020 Buy $2.50 12,677,490 31,693,725 14,000,000 Jun 12, 2020, 05:34 PM
Frazier Life Sciences VIII, L.P. 10% Owner Jan 09, 2020 Sale $5.00 50,000 250,010 1,299,953 Jan 13, 2020, 10:47 AM
Tommasi Ruben Chief Scientific Officer Dec 21, 2018 Option Exercise $3.45 22,024 75,921 22,024 Dec 26, 2018, 04:45 PM
Topper James N Director Sep 28, 2018 Buy $15.00 375,887 5,638,305 1,349,953 Oct 02, 2018, 09:42 PM
Sofinnova Venture Partners IX, L.P. 10% Owner Sep 28, 2018 Buy $15.00 337,724 5,065,860 1,180,178 Oct 02, 2018, 09:41 PM
Preston Heather Director Sep 28, 2018 Buy $15.00 337,724 5,065,860 1,180,178 Oct 02, 2018, 09:40 PM
Pivotal bioVenture Partners Fund I, L.P. 10% Owner Sep 28, 2018 Buy $15.00 337,724 5,065,860 1,180,178 Oct 02, 2018, 09:39 PM
GALAKATOS NICHOLAS Director Sep 28, 2018 Buy $15.00 453,395 6,800,925 1,623,405 Oct 02, 2018, 09:38 PM
Frazier Life Sciences VIII, L.P. 10% Owner Sep 28, 2018 Buy $15.00 375,887 5,638,305 1,349,953 Oct 02, 2018, 09:38 PM
Clarus Lifesciences III, L.P. 10% Owner Sep 28, 2018 Buy $15.00 453,395 6,800,925 1,623,405 Oct 02, 2018, 09:36 PM
ASTRAZENECA PLC 10% Owner Sep 28, 2018 Buy $15.00 246,666 3,699,990 2,164,855 Oct 02, 2018, 09:35 PM
TPG Group Holdings (SBS) Advisors, Inc. Former 10% Owner Sep 28, 2018 Buy $15.00 262,539 3,938,085 1,020,748 Oct 02, 2018, 04:46 PM
Novo Holdings A/S 10% Owner Sep 28, 2018 Buy $15.00 1,089,835 16,347,525 2,181,843 Oct 01, 2018, 04:36 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
Ronsheim Matthew Chief, Pharma Sciences & MFG. 11/02/2021 10,787
Keiley Elizabeth M General Counsel 11/02/2021 10,787
Altarac David Chief Medical Officer 11/02/2021 10,787
Mueller John Patrick Chief Development Officer 11/02/2021 11,487
Perros Manoussos President and CEO 11/02/2021 34,410
Gutch Michael CFO and Chief Business Officer 11/02/2021 10,787
Tommasi Ruben Chief Scientific Officer 11/02/2021 10,787
Perros Manoussos See Remarks 10/19/2021 38,197
Mueller John Patrick Chief Development Officer 10/19/2021 12,763
Gutch Michael See Remarks 10/19/2021 11,991
Tommasi Ruben Chief Scientific Officer 10/19/2021 11,991
Keiley Elizabeth M General Counsel 10/19/2021 11,991
Altarac David Chief Medical Officer 10/19/2021 11,991
Ronsheim Matthew See Remarks 10/19/2021 11,991
Innoviva, Inc. 10% Owner 09/01/2020 12,499,999
Innoviva, Inc. 10% Owner 06/11/2020 31,693,725
Frazier Life Sciences VIII, L.P. 10% Owner 01/09/2020 250,010
Tommasi Ruben Chief Scientific Officer 12/21/2018 75,921
Topper James N Director 09/28/2018 5,638,305
Sofinnova Venture Partners IX, L.P. 10% Owner 09/28/2018 5,065,860
Preston Heather Director 09/28/2018 5,065,860
Pivotal bioVenture Partners Fund I, L.P. 10% Owner 09/28/2018 5,065,860
GALAKATOS NICHOLAS Director 09/28/2018 6,800,925
Frazier Life Sciences VIII, L.P. 10% Owner 09/28/2018 5,638,305
Clarus Lifesciences III, L.P. 10% Owner 09/28/2018 6,800,925
ASTRAZENECA PLC 10% Owner 09/28/2018 3,699,990
TPG Group Holdings (SBS) Advisors, Inc. Former 10% Owner 09/28/2018 3,938,085
Novo Holdings A/S 10% Owner 09/28/2018 16,347,525
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
03/31/2022
09/30/2021
14.29%
View
2Q
03/31/2022
06/30/2021
22.37%
View
3Q
03/31/2022
03/31/2021
29.06%
View
4Q

Period of Report: 03/31/2022

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2021
14.29%
2Q
06/30/2021
22.37%
3Q
03/31/2021
29.06%
4Q